
|Podcasts|November 13, 2009
Regulatory and Safety: Obesity Drugs
Advertisement
Diabetes & Obesity Series
Safety and Regulatory Aspects of Obesity Drugs
Subscribe to RSS feed of this series
Dr. David Orloff
Executive Director of Regulatory Affairs
Medpace
Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.
Others in the Series
Diabetes Resources
- Articles, Multimedia
Diabetes Drugs in Development, 2009
Associations and Societies
Clinical Trials
Obesity Resources
Articles, Multimedia
Associations and Societies
Clinical Trials
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI
2
SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D
3
Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions
4
SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations
5



